Literature DB >> 31394407

Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation.

Jungang Chen1, Luis Del Valle2, Hui-Yi Lin3, Karlie Plaisance-Bonstaff4, J Craig Forrest5, Steven R Post1, Zhiqiang Qin6.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) causes several cancers such as Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL). PD-1/PD-Ls immune checkpoint molecules play important roles in cancer cell immune escape. The expression of PD-1/PD-Ls and their regulation by oncogenic viruses, in particular KSHV, remain largely undefined. Here we demonstrate strong PD-1/PD-L1/PD-L2 expression in KS tissues from a cohort of HIV + patients. We found that induction of KSHV lytic reactivation significantly upregulates PD-L1 expression on infected tumor cells, potentially through several major cellular signaling pathways and IL-1β, which may represent a novel mechanism for virus-associated tumor cell immune escape.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KSHV; Kaposi's sarcoma; PD-1; PD-L1; PD-L2

Mesh:

Substances:

Year:  2019        PMID: 31394407      PMCID: PMC6733645          DOI: 10.1016/j.virol.2019.07.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.

Authors:  Jungang Chen; Lu Dai; Lindsey Barrett; Jennifer James; Karlie Plaisance-Bonstaff; Steven R Post; Zhiqiang Qin
Journal:  Commun Biol       Date:  2021-06-03

Review 2.  Current and Future Tools for Diagnosis of Kaposi's Sarcoma.

Authors:  Nicolas Dupin; Aude Jary; Samia Boussouar; Charlotte Syrykh; Amir Gandjbakhche; Sébastien Bergeret; Romain Palich
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

3.  Extracellular Vesicles Tropism: A Comparative Study between Passive Innate Tropism and the Active Engineered Targeting Capability of Lymphocyte-Derived EVs.

Authors:  Tania Limongi; Francesca Susa; Bianca Dumontel; Luisa Racca; Michela Perrone Donnorso; Doriana Debellis; Valentina Cauda
Journal:  Membranes (Basel)       Date:  2021-11-18

Review 4.  Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.

Authors:  Marc-Antoine Valantin; Léna Royston; Maxime Hentzien; Aude Jary; Alain Makinson; Marianne Veyri; Sylvie Ronot-Bregigeon; Stéphane Isnard; Romain Palich; Jean-Pierre Routy
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

5.  Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target.

Authors:  Jungang Chen; Lindsey Barrett; Zhen Lin; Samantha Kendrick; Shengyu Mu; Lu Dai; Zhiqiang Qin
Journal:  J Cell Mol Med       Date:  2022-03-22       Impact factor: 5.295

Review 6.  Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis.

Authors:  Lindsey Barrett; Jungang Chen; Lu Dai; Karlie Plaisance-Bonstaff; Luis Del Valle; Zhiqiang Qin
Journal:  Front Cell Infect Microbiol       Date:  2020-10-30       Impact factor: 5.293

7.  Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer.

Authors:  Marine Baron; Cathia Soulié; Armelle Lavolé; Lambert Assoumou; Baptiste Abbar; Baptiste Fouquet; Alice Rousseau; Marianne Veyri; Assia Samri; Alain Makinson; Sylvain Choquet; Julien Mazières; Solenn Brosseau; Brigitte Autran; Dominique Costagliola; Christine Katlama; Jacques Cadranel; Anne-Geneviève Marcelin; Olivier Lambotte; Jean-Philippe Spano; Amélie Guihot
Journal:  Cells       Date:  2022-03-17       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.